July 11, 2017 | Jonathan Pan of Aevi Genomic Medicine is featured on this podcast from Cambridge Health Tech Institute for the Next Generation Diagnostic Summit. Topics include precision medicine outside of oncology, unique genomic approaches, implementation in routine care, and more. Here is a sample of the discussion that takes place. Podcast
CHI: We have discussed personalized and precision medicine for over a decade, but the only therapeutic area we have seen visible progress in is oncology. Your company Aevi Genomic Medicine is working on breaking this paradigm. Can you share why and how you are doing this?
Jonathan Pan: … I think precision medicine has actually been around us for quite some time, outside of oncology actually. We think about drugs like Sovaldi, Colidica, Selzentry, all of them require a precision medicine approach, but as one can see, oncology has definitely taken the limelight over the past few years and is pretty synonymous with precision medicine.
I think when we get outside of oncology, it gets a little bit interesting in terms of the ideology of the disease and how diseases are diagnosed and then treated. I think if we look at the example of a product like Plavix where we look at pharmecogenomic markers to look at the metabolism of the drug, that in and of itself is a precision medicine looking at the pharmecogenomic markers that determine response to the medicine. From that perspective it's been around for quite a while.